The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

about

First line vs delayed transplantation in myeloma: Certainties and controversies

P2860

Q26745957-4D3B033D-018D-4F47-9047-6B85750C235C

P2860

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

Item

http://www.wikidata.org/entity/Q57903975

description

article

@en

im April 2014 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у квітні 2014

@uk

name

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

@en

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

@nl

type

Item

label

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

@en

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

@nl

prefLabel

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

@en

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

@nl

P1476

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

@en

P2093

Athanasia Zeisig

http://www.w3.org/2001/XMLSchema#string

Claire Stephens

http://www.w3.org/2001/XMLSchema#string

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

Gowri Vijayaraghavan

http://www.w3.org/2001/XMLSchema#string

Ian Titley

http://www.w3.org/2001/XMLSchema#string

Lorenzo Melchor

http://www.w3.org/2001/XMLSchema#string

Ricardo Morilla

http://www.w3.org/2001/XMLSchema#string

P2860

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Lenalidomide after stem-cell transplantation for multiple myeloma

International uniform response criteria for multiple myeloma.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

Lenalidomide mode of action: linking bench and clinical findings.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

P304

2665-2668

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2014.900765

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24660850

http://www.w3.org/2001/XMLSchema#string

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

about

P2860

P2860

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698